Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The move up comes as the S&P 500 and Nasdaq Composite gained ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Acquired DNA mutations found in the SERPINA1 gene can protect liver cells from damage in patients with alpha-1 antitrypsin ...

Prime Medicine, Inc. announced the launch of a preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function, utilizing their ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...